Vol. 6 No. 3 (2026)
Reimbursement Reviews

Daridorexant (Quviviq)

decorative image of the issue cover

Published March 2, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Daridorexant (Quviviq), 25 mg oral tablet, 50 mg oral tablet.
  • Indication: Quviviq (daridorexant) is indicated for the management of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.